Articles related to FDA

Zevtera® (ceftobiprole medocaril) provides a significant advancement in treating serious bacterial infections, demonstrating high efficacy against both MRSA and MSSA in recent phase 3 clinical trials.

Healthcare providers should be alert to symptoms of methanol poisoning, which can include vomiting, blurred vision, and seizures, particularly in patients who may have used recalled hand sanitizers containing methanol.

Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.

The FDA’s recent warnings about high-concentration lidocaine in OTC analgesics spotlight a significant health risk, emphasizing the need for healthcare professionals to guide patients in choosing safe and approved pain relief options.